| Summary: | The development of the first drug-like selective angiotensin II type 2 (AT 2 ) receptor agonist (22) derived from the non-selective angiotensin II type 1 (AT 1 ) receptor/AT 2 receptor agonist L-162,313 is presented. Compound 22 with a K i value of 0.4 nM for the AT 2 receptor and a K i > 10 μM for the AT 1 receptor induces outgrowth of neurite cells, stimulates p42/p44 mapk , enhances in vivo duodenal alkaline secretion in Sprague-Dawley rats and lowers the mean arterial blood pressure in anaesthetised spontaneously hypertensive rats. Thus, the peptidomimetic 22 exerts a similar biological response as the endogenous peptide angiotensin II after selective activation of the AT 2 receptor. In addition, Compound 22 has a bioavailability of 20—30% after oral administration and a half-life estimated to four hours in the rat. Compound 22 will therefore serve as a valuable research tool enabling studies of the function of the AT 2 receptor in more detail.
|
|---|